Alpha-Gal Syndrome, Heart Valves and Cardiac Surgery


Heart surgery is one of the few places in medicine where a person receives large amounts of animal material straight into the bloodstream or sewn into the body. Replacement heart valves are often made from pig or cow tissue, patches that close holes in the heart can be cut from cow pericardium, the blood thinner used during the operation comes from pig or cow tissue, and the sponges and pastes that stop bleeding can be made of gelatin. For people with alpha-gal syndrome (AGS), an allergy to a sugar found in the tissues of non-primate mammals, every one of these is a possible exposure. This page goes deeper into that one setting: what the laboratory studies found, what happened to real patients in published reports, how heart teams described their planning, and how much is still unknown.

The broader background is covered elsewhere on this site: the allergy itself on the Alpha-Gal Syndrome main page, the full list of mammal-derived medicines on Cross-Reactive Medications, and the link between alpha-gal antibodies and coronary plaque on Alpha-Gal Syndrome and Cardiovascular Risk.


Table of Contents

  1. Why Animal-Derived Medical Products Carry Alpha-Gal
  2. The Animal-Origin Materials Used in Heart Procedures
  3. Patients' Serum Binds Valves and Patches in the Laboratory
  4. Antibodies Against Valve Sugars Track With Valve Wear
  5. A 2026 Review Found Six Studies and Mixed Outcomes
  6. Heparin Reactions Range From None to Cardiac Arrest
  7. Gelatin Hemostats and Plasma Substitutes Have Caused Reactions
  8. Valve Replacements Have Been Completed With Animal Valves
  9. How Published Teams Screened and Planned
  10. What Is Not Known
  11. Key Research Papers
  12. Connections
  13. Featured Videos

Why Animal-Derived Medical Products Carry Alpha-Gal

Galactose-alpha-1,3-galactose, shortened to alpha-gal, is a carbohydrate made by the tissues of mammals other than humans and certain Old World primates. A 2024 narrative review from the University of Virginia describes it as present in a wide range of products derived from mammals, including milk, organs, skeletal muscle and gelatin, as well as products prepared with mammalian cells or ingredients (Zvara 2024). Because the sugar is part of the animal's tissue itself, it does not disappear when that tissue is turned into a medical product.

The same review notes that medications and bioprosthetic implants derived from mammals have caused allergic reactions in people with alpha-gal syndrome, and it describes cardiac surgery in particular as high risk: unfractionated heparin has a bovine (cow) or porcine (pig) origin and is given in large doses for cardiopulmonary bypass, the heart-lung machine, and bioprosthetic valves have similar origins (Zvara 2024).

The sugar survives even the industrial treatments that strip cells out of animal tissue. A 2022 laboratory study concluded that "despite commercial decellularization processes, alpha-gal continues to be present in animal-derived medical products, including bioprosthetic valves" (Kuravi 2022).

Two kinds of antibody appear in this research, and they mean different things. Immunoglobulin E is the allergy antibody; it is what causes hives, a drop in blood pressure and anaphylaxis within minutes to hours. Immunoglobulin G is a different class of antibody; the valve-durability research below is largely about immunoglobulin G and about people who do not necessarily have the allergy at all.

The Animal-Origin Materials Used in Heart Procedures

The published reports read for this page name these categories of animal-derived material in the heart operating room and catheterization laboratory:

Protamine, the drug used at the end of heart surgery to reverse heparin, is a different case. A 2023 review describes it as "a highly basic protein isolated from salmon sperm" and as the only clinically available agent that reverses unfractionated heparin (Levy 2023). Fish are not mammals, so protamine is not a mammalian product. None of the records read for this page tested protamine for alpha-gal. Protamine does cause its own reactions: the same review describes adverse reactions ranging from widened blood vessels to life-threatening heart and lung dysfunction and shock, with the most severe appearing to be hypersensitivity reactions through immunoglobulin E and/or immunoglobulin G (Levy 2023). A 2026 review on cardiovascular hypersensitivity likewise lists protamine and iodinated contrast among medicines that can set off life-threatening reactions through multiple immune pathways (Sami 2026). Those reactions are a separate problem from alpha-gal.

Patients' Serum Binds Valves and Patches in the Laboratory

The first direct test came from a group at Duke University and the University of North Carolina. They took blood serum from people with alpha-gal syndrome and used immunoblot and tissue-staining methods to see whether the patients' immunoglobulin E would stick to common cardiac materials and valves (Kuravi 2022). The result was clear in the test tube: "AGS serum showed strong reactivity to all of the commercially available, nonhuman products tested, including various decellularized cardiac patch materials and bioprosthetic aortic valves." The same serum did not react to tissue prepared from alpha-gal knockout pigs, animals bred without the gene that makes the sugar. The authors wrote that the finding "may have serious potential implications for sensitized patients undergoing cardiac surgery, including early valve failure and accelerated coronary artery disease" (Kuravi 2022).

A 2026 study then counted how much alpha-gal the valves carry. Twelve commercial bioprosthetic valve models were analysed in the laboratory (Colli 2026):

The authors concluded that commercially available valves "retain a substantial immunogenic burden" from alpha-gal (Colli 2026). Both of these studies were done on tissue and serum in the laboratory. Neither one followed patients, so neither shows how often a reaction or early valve failure happens in a real person.

Antibodies Against Valve Sugars Track With Valve Wear

Bioprosthetic valves are inherently susceptible to structural valve degeneration, which the 2026 valve study attributes to a combination of mechanical stress, fat infiltration, unstable glutaraldehyde cross-links and progressive calcification (Colli 2026). A 2022 study in Nature Medicine asked whether ordinary immunoglobulin G antibodies against two animal sugars, alpha-gal and a second sugar called N-glycolylneuraminic acid (Neu5Gc), could be part of the answer (Senage 2022).

It is the largest study on the question. The international cohort enrolled 1668 patients with up to 15 years of follow-up after aortic valve replacement (34 ± 43 months on average) and collected 4,998 blood samples (Senage 2022). The findings:

The authors concluded that valves made from donor tissue lacking these two sugars "could be less prone to immune-mediated deterioration and have improved durability" (Senage 2022). This study was about valve recipients in general, not about people with alpha-gal syndrome, and it measured immunoglobulin G rather than the allergy antibody. Its relevance here is that it shows the immune system does respond to the sugars on a bioprosthetic valve for years after surgery.

A 2026 Review Found Six Studies and Mixed Outcomes

A 2026 review from Columbia University and Duke University searched three databases (Embase, PubMed and Scopus) for original human studies on alpha-gal and bioprosthetic valve degeneration published between January 2014 and December 2025 (Gosden 2026). Six studies met its criteria, which shows how thin the human evidence still is.

The review reported (Gosden 2026):

The authors concluded that immune recognition of alpha-gal "may contribute" to valve degeneration "based on the limited available evidence", that its broader significance "remains uncertain", and that larger prospective studies are required to establish cause and effect and to guide prevention (Gosden 2026). They add that recognising the mechanism may eventually inform how valves are chosen.

Heparin Reactions Range From None to Cardiac Arrest

The best numbers on heparin come from a University of Virginia review of 8819 cardiac operations from 2007 to 2019, which found 17 patients (0.19%) with a positive alpha-gal test before surgery; 4 of them (24%) had a severe allergic reaction, and in the 8 patients with a recent alpha-gal immunoglobulin E level, 4 (50%) reacted (Hawkins 2021). Those who reacted had a median alpha-gal level of 75 IU/mL against 8 IU/mL in those who did not, while heparin doses did not differ. The study is described in more detail on Cross-Reactive Medications; its authors concluded there is "up to a 50% risk of serious allergic reaction to heparin for cardiopulmonary bypass" in this rare group (Hawkins 2021).

Individual case reports show the whole range of outcomes:

The non-mammalian blood thinners that exist are listed on Cross-Reactive Medications. A 2024 case report notes that there are currently no guidelines for heparin administration in alpha-gal patients (Taira 2024).

Gelatin Hemostats and Plasma Substitutes Have Caused Reactions

Gelatin is the other large mammalian exposure in the operating room. Its link to alpha-gal was measured in a 2012 study, which found alpha-gal in bovine gelatin colloids at about 0.44 to 0.52 μg per gram of gelatin, and found that both of 2 patients with anaphylaxis caused by gelatin colloid had a positive gelatin skin test (Mullins 2012). The food side of that study is covered on Complete Mammalian Foods List.

Case reports from surgery:

None of these four reports is described as a heart operation. In two of the cases (Lied 2019; Henderson 2026), alpha-gal syndrome was only recognised after the reaction in the operating room.

Valve Replacements Have Been Completed With Animal Valves

Against the laboratory warnings, most published patient outcomes so far have been uneventful in the short term.

The 155-patient cohort. A prospective study at Duke University measured alpha-gal immunoglobulin E in patients having a bioprosthetic aortic valve put in between January 2022 and January 2023 (Aykut 2025). Of 155 patients, 32.7% (n = 19) of the surgical valve patients and 29.9% (n = 29) of the transcatheter valve patients had detectable immunoglobulin E against alpha-gal. None of them had a serious allergic reaction or died in hospital, and hospital stay and valve function were similar across groups. The authors note that this applies to immediate valve function after surgery; the study did not follow the valves over years (Aykut 2025). Detectable antibody is not the same as diagnosed alpha-gal syndrome, and most of these patients were not known to have the allergy.

The 2026 case series. An anesthesiology group at the University of North Carolina reported three patients with documented alpha-gal syndrome who had transcatheter aortic valve replacement (TAVR) with bovine or porcine valves (Lari 2026). All three were evaluated by allergists before the procedure, and two received no drug pre-treatment. Heparin caused no reactions, recovery showed no immediate or delayed allergic response, and follow-up of 4 to 6 years showed no structural valve deterioration attributable to alpha-gal syndrome. The authors conclude that "perioperative hypersensitivity appears to be rare in this population" (Lari 2026). Three patients is a small number, and the parent page Alpha-Gal Syndrome and Cardiovascular Risk summarises the same series.

Single cases:

Successful cases are more likely to be written up than routine ones, and short-term success says nothing about how long these valves will last.

How Published Teams Screened and Planned

No guideline sets out how to care for a person with alpha-gal syndrome during heart surgery. What exists is a handful of published approaches, each from one team:

The Anaphylaxis Emergency Plan page covers the signs hospitals treat as an emergency. Decisions about any specific operation, valve or pre-treatment belong with the surgical team and an allergist.

What Is Not Known

Key Research Papers

  1. Kuravi KV, Sorrells LT, Nellis JR, Rahman F, Walters AH, Matheny RG, Choudhary SK, Ayares DL, Commins SP, Bianchi JR, Turek JW. Allergic response to medical products in patients with alpha-gal syndrome. J Thorac Cardiovasc Surg. 2022;164(6):e411-e424. PubMed PMID: 33933257
  2. Gosden J, Ascione G, Wolf S, Turek JW, George I. Alpha-gal xenoantigens in bioprosthetic valve recipients: clinical implications for bioprosthesis longevity. J Cardiothorac Surg. 2026;21(1):719. PubMed PMID: 42226205
  3. Lari K, Leghari S, Smeltz AM, Patel D, Teeter EG. Alpha-Gal Syndrome-A Case Series of Successful Transcatheter Mammalian-Derived Aortic Valve Replacements. Semin Cardiothorac Vasc Anesth. 2026;30(3):216-220. PubMed PMID: 42375124
  4. Colli A, Zilla P, Calafiore AM, Padalino M, Naso F, George I. Quantification of Alpha-Gal Expression in Commercial BioProsthetic Heart Valves and Its Potential Mitigation. Struct Heart. 2026;10(3):100739. PubMed PMID: 41646629
  5. Senage T, Paul A, Le Tourneau T, Fellah-Hebia I, Vadori M, Bashir S, et al. The role of antibody responses against glycans in bioprosthetic heart valve calcification and deterioration. Nat Med. 2022;28(2):283-294. PubMed PMID: 35177855
  6. Hawkins RB, Wilson JM, Mehaffey JH, Platts-Mills TAE, Ailawadi G. Safety of Intravenous Heparin for Cardiac Surgery in Patients With Alpha-Gal Syndrome. Ann Thorac Surg. 2021;111(6):1991-1997. PubMed PMID: 33031779
  7. Aykut B, Lim HK, Ngeve SM, Hoover A, Medina CK, Scherba J, Menken A, Overbey DM, Omer TM, Commins SP, Nellis JR, Turek JW. Perioperative Outcomes After Bioprosthetic Valve Replacement in Patients Sensitized to Alpha-Gal. Ann Thorac Surg Short Rep. 2025;3(1):264-268. PubMed PMID: 40098868
  8. Zvara J, Smith AL, Mazzeffi MA, Kleiman AM, Tanaka K, Smith AR, Wilson JM, McNeil JS. Alpha-Gal Syndrome and Cardiac Surgery. J Cardiothorac Vasc Anesth. 2024;38(11):2805-2811. PubMed PMID: 39097488
  9. Sami N, Parikh MA, Mihatov N, Frishman WH, Peterson SJ. The Alpha-Gal Syndrome and Hypersensitivity to Biomaterials: Understanding Xenoimmunity. Cardiol Rev. 2026. Online ahead of print. PubMed PMID: 41703677
  10. Khanipour R, Bera RK, Suarez I, Soltani Moghadam A, Mattumpuram J. Heparin-Induced Anaphylaxis With Cardiac Arrest in a Patient With Alpha-Gal Syndrome: A Case Report. Cureus. 2026;18(6):e110413. PubMed PMID: 42416968
  11. Henderson JJ, Saleem D, George E, Still S. Intraoperative Anaphylaxis in the Setting of Undiagnosed Alpha-Gal Syndrome: A Heart Team Clinical Conundrum. JACC Case Rep. 2026;31(1):106033. PubMed PMID: 41504355
  12. Mawhirt SL, Banta E. Successful intravenous heparin administration during coronary revascularization surgery in a patient with alpha-gal anaphylaxis history. Ann Allergy Asthma Immunol. 2019;123(4):399-401. PubMed PMID: 31150778
  13. McRae AS, Tidwell WP, Patel S, Lombard FW. Heparin desensitisation prior to cardiopulmonary bypass in a patient with alpha-gal allergy. Anaesth Rep. 2022;10(2):e12203. PubMed PMID: 36561536
  14. Patel R, Patel A, Biswas R, Hsieh B, Ramasamy D, Patel C. Managing Alpha-Gal Allergy in a Case of Bioprosthetic TAVR. Case Reports Immunol. 2026;2026:8190714. PubMed PMID: 42040183
  15. Sami N, Ravishankar B, Worku B, Khatib D, McGintee E, Sacchi T, Dogan O, Perk G, Reisman M, Mihatov N. Alpha-Gal Syndrome and Aortic Valve Replacement. JACC Case Rep. 2025;30(32):105478. PubMed PMID: 41106900
  16. Chen S, Zeigler S. Safe Implantation of a Bovine Bioprosthetic Aortic Valve in a Patient With Galactose-α-1,3-Galactose Allergy. Ann Thorac Surg. 2024;118(4):950-952. PubMed PMID: 38996861
  17. Taira K, Kanade R, Yammine M, Tannous H, Kumar S. Alpha gal syndrome, a relative not absolute contraindication to the use of bovine pericardium to close an intracardiac septal defect: a case report. J Cardiothorac Surg. 2024;19(1):221. PubMed PMID: 38627833
  18. Dang Van S, Fouquet O, Jeanneteau A, Leclere JM, Baufreton C. Aortic homograft for aortic valve replacement in patient with Alpha-Gal allergy. Gen Thorac Cardiovasc Surg. 2021;69(11):1499-1501. PubMed PMID: 34279773
  19. Mullins RJ, James H, Platts-Mills TA, Commins S. Relationship between red meat allergy and sensitization to gelatin and galactose-α-1,3-galactose. J Allergy Clin Immunol. 2012;129(5):1334-1342.e1. PubMed PMID: 22480538
  20. Lied GA, Lund KB, Storaas T. Intraoperative anaphylaxis to gelatin-based hemostatic agents: a case report. J Asthma Allergy. 2019;12:163-167. PubMed PMID: 31354307
  21. Holbert SE, Patel D, Rizk T, Dimitri NG, Jones M. Intraoperative Anaphylaxis in Response to Hemostatic Agents With Protein Derivatives. Cureus. 2020;12(8):e9881. PubMed PMID: 32963920
  22. Uyttebroek A, Sabato V, Bridts CH, De Clerck LS, Ebo DG. Anaphylaxis to succinylated gelatin in a patient with a meat allergy: galactose-α(1, 3)-galactose (α-gal) as antigenic determinant. J Clin Anesth. 2014;26(7):574-6. PubMed PMID: 25439422
  23. Serrier J, Khoy K, Ollivier Y, Gervais R, Le Moel G, Lafosse M, Johnson A, Le Mauff B, Mariotte D. Recurrent anaphylaxis to a gelatin-based colloid plasma substitute and to cetuximab following sensitisation to galactose-alpha-1,3-galactose. Br J Anaesth. 2021;126(6):e200-e202. PubMed PMID: 33810867
  24. Levy JH, Ghadimi K, Kizhakkedathu JN, Iba T. What's fishy about protamine? Clinical use, adverse reactions, and potential alternatives. J Thromb Haemost. 2023;21(7):1714-1723. PubMed PMID: 37062523

PubMed Topic Searches

  1. PubMed: alpha-gal and bioprosthetic heart valves
  2. PubMed: alpha-gal and heparin anaphylaxis
  3. PubMed: galactose-alpha-1,3-galactose and cardiac surgery
  4. PubMed: alpha-gal, gelatin and anaphylaxis in surgery
  5. PubMed: anti-Gal antibodies and bioprosthetic valve deterioration
  6. PubMed: alpha-gal and pericardial patches

Back to Table of Contents

Connections